HRSA’s Renewed Focus on Contract Pharmacy Revenue Flow
During HRSA’s 2026 audit season, several disproportionate share hospitals were cited not for diversion or duplicate discounts, but for failing to track how much profit their contract pharmacies retained from 340B prescriptions. That’s a genuine shift. For years, HRSA auditors stayed narrowly focused on eligibility determinations and price integrity. Now they’re asking for contract-level detail about revenue splits, and proof that savings actually serve patients. The message couldn’t be clearer: transparency isn’t just about compliance anymore; it’s about stewardship.
This spring, a large urban DSH facility I advised received a draft audit report with eight findings. Five involved stale contract pharmacy agreements that paid pharmacies “cost plus $X” without any process for reconciling rebates or admin fees. HRSA demanded disclosure of the exact profit retained by the chain. The entity couldn’t produce it. And that’s becoming familiar. If your reconciliation reports can’t pinpoint where the profit sits, you’re already exposed.
Where HRSA Guidance Ends and Data Gaps Begin
HRSA’s authority under Section 340B of the Public Health Service Act stops short of dictating how entities spend their savings. Yet the 2025 Oversight Update introduced a new bar: covered entities must “demonstrate the financial impact of contract pharmacy arrangements as part of program integrity reviews.” Translation, show your math. HRSA still can’t set revenue-share limits, but it can question whether you even know the numbers.
Pharmacy chains say their administrative fees cover inventory management, data exchange, and dispensing costs. Covered entities reply that some fees devour half their margin. Since HRSA doesn’t publish pharmacy-level data, benchmarking “reasonable” compensation is impossible. And the opacity deepens when manufacturers restrict pharmacy access through ESP submissions or reduced allocations. Entities cling to what’s left, often on poor terms, just to keep prescriptions moving. That’s when compliance turns fragile and accountability slips.
In reality, most administrators see only what their TPA reports show, and those reports track inventory, not money. So when HRSA asks, “what’s your retained savings per prescription?” most respond with a rough average. That worked a few years back. Not now. Not in 2026.
Rebate Capture and Manufacturer Accountability
The rebate issue now sits center stage. Since manufacturers began conditioning contract pharmacy participation on sending claims data through 340B ESP, entities have struggled to measure lost rebates when claims get invalidated. HRSA’s auditors in 2026 are explicitly requiring “documentation of rebate capture or loss due to manufacturer restrictions.” That’s new, and it reshapes what “complete” documentation looks like.
One community health center I work with reconciled its 2025 inventory and found a $487,000 shortfall against expected savings. Root cause? Four major manufacturers invalidated retail contract pharmacy claims due to slow data uploads. HRSA didn’t penalize the loss but cited inadequate documentation of corrective steps. Put plainly, HRSA won’t police the manufacturers, but it expects entities to prove they’ve analyzed the financial hit and planned around it.
Forward-thinking compliance officers are already adding rebate-tracking fields into TPA feeds so they can quantify lost opportunity. Smart move. When HRSA folds rebate capture into its oversight narrative, numbers will win credibility. The broader policy story is that the Advisory Opinion litigation from 2025 is still unsettled, but auditors have clearly embraced the transparency theme. They no longer ask only what savings you generate; they ask how much survives the process, and whether you understand why you lose the rest. Look, that’s progress, even if it stings.
How Covered Entities Prove Accountability Now
Let’s be honest: too many hospitals still treat contract pharmacy revenue as a mystery fund. Cash flows from TPA to clearinghouse to pharmacy, then drips into the entity’s account. By the time finance sees it, half the 340B value has evaporated. HRSA’s auditors are done with “our TPA handles that.” In 2026, that’s a red flag. Every covered entity needs clear internal documentation identifying how much of each 340B margin the pharmacy retains and what comes back to the entity, by name, by date, by verification. HRSA hasn’t issued a model template, but the expectation is real.
There’s also mounting pressure, from congressional staff and a few state Medicaid agencies, that entities show how 340B proceeds tangibly expand access or patient care. Some states already require annual “benefit statements” for cost report reconciliation. Stack that atop HRSA’s new audit lens, and the old line “we reinvest savings in care” no longer holds weight without receipts.
Operationally, covered entities should run quarterly internal reviews focused solely on the money trail. Sample prescriptions, trace them through the reimbursement chain, and confirm the split. Bring those findings to your 340B compliance committee. If your contracts predate 2023, you’re already late to rewrite them. HRSA can’t set revenue-sharing rules outright, but “insufficient documentation of program benefit” is plenty to earn a corrective action plan. And no one wants that letter.
The reality is, 2026 oversight isn’t about redefining 340B eligibility, it’s about showing your financial homework. HRSA is tightening the link between integrity and fiscal accountability, using contract pharmacy profit retention as the lever. Whether that matures into new guidance or just an audit-era trend, who knows. But waiting isn’t a strategy. Trace your cash flow now, track manufacturer impacts quarterly, and get comfortable proving that you don’t just comply, you understand where the money goes.